Valuation: Exact Sciences Corporation

Market Cap 20.03B 17.57B 16.6B 15.12B 28.31B 1,919B 28.52B 199B 76.92B 981B 75.19B 73.56B 3,151B P/E 2024
-10.1x
P/E 2025 -92.2x
Enterprise Value 21.6B 18.95B 17.9B 16.31B 30.53B 2,070B 30.75B 214B 82.96B 1,057B 81.09B 79.33B 3,399B EV / Sales 2024
4.4x
EV / Sales 2025 6.42x
Free-Float
98.24%
Yield 2024 *
-
Yield 2025 -
1 day+0.95%
Current year+3.30%
Current year 101.51
Extreme 101.51
104.98
1 year 52.85
Extreme 52.85
104.98
3 years 38.81
Extreme 38.8118
104.98
5 years 29.27
Extreme 29.27
104.98
10 years 13.05
Extreme 13.05
159.54
Date Insider Type Main position Quantity % Market Cap. Importance
3/23/26 A Issuer sale

Director

28,899 0.0151%
3/23/26 A Free

Executive/Senior Manager

199,374 0.1044%
3/23/26 A Issuer sale

Director

20,558 0.0108%
Change 5-day change 1-year change 3-year change Capi.($)
+0.95%-.--%+95.84%+55.51% 20.03B
+1.85%+7.32%+421.33%+144.44% 4.98B
-0.47%+2.87%+122.62%+421.81% 4.7B
-6.41%+14.16%+35.86%+98.73% 3.65B
+3.76%+18.30%+326.52%+764.04% 3.29B
+2.50%+13.65%-7.45%-15.51% 2.58B
-4.59%-8.24%+48.11% - 1.72B
-0.58%+0.59%+36.00%+59.25% 1.14B
-0.65%+9.04%+169.50%-22.13% 1.13B
+5.08%+8.18%-21.14%+125.71% 629M
Average +0.14%+6.66%+122.72%+181.32% 4.39B
Weighted average by Cap. +0.35%+4.67%+138.75%+160.72%

Financials

2024 2025
Net sales 2.76B 2.42B 2.29B 2.08B 3.9B 264B 3.93B 27.36B 10.6B 135B 10.36B 10.13B 434B 3.25B 2.85B 2.69B 2.45B 4.59B 311B 4.62B 32.2B 12.47B 159B 12.19B 11.93B 511B
Net income -1.03B -903M -853M -777M -1.45B -98.61B -1.46B -10.2B -3.95B -50.38B -3.86B -3.78B -162B -208M -182M -172M -157M -294M -19.93B -296M -2.06B -799M -10.18B -781M -764M -32.72B
Net Debt 1.74B 1.52B 1.44B 1.31B 2.46B 167B 2.47B 17.23B 6.67B 85.09B 6.52B 6.38B 273B 1.57B 1.38B 1.3B 1.19B 2.22B 150B 2.24B 15.57B 6.03B 76.88B 5.9B 5.77B 247B
Logo Exact Sciences Corporation
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. It offers a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. Its portfolio includes brands such as Cologuard and Oncotype DX, along with solutions like Cancerguard for blood-based analysis of molecular information across multiple cancers and Oncodetect for molecular residual disease and recurrence monitoring. Its flagship screening products, the Cologuard and Cologuard Plus tests, are patient-friendly, non-invasive, stool-based DNA (sDNA) screening tests that utilize a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Its Cancerguard test is designed to detect multiple cancers in their earliest stages from a single blood draw. It offers predefined genetic tests for all clinically relevant genes, and whole genome (PGnome) sequencing tests.
Employees
7,150
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
AAA
  1. Stock Market
  2. Stocks
  3. EXAS Stock